Mallinckrodt's InfaCare Buy Leaves Room For Further Diversifying M&A

UK-based Mallinckrodt's purchase of InfaCare gives it a late-stage asset for severe jaundice in infants while leaving room for further M&A.

Newborn
Buying InfaCare Will Give Mallinckrodt The Severe Jaundice Asset Stannsoporfin • Source: Shutterstock

By buying privately held InfaCare Pharmaceutical Corp., the UK specialty pharma Mallinckrodt PLC will diversify further into therapies for neonatal and pediatric patients while retaining sufficient fire power for more targeted acquisitions later, analysts say.

Mallinckrodt is paying up to $425m to acquire InfaCare and its late-stage medicine stannsoporfin which is being developed to treat...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip